PURPOSE To study the effect of the concomitant use of brinzolamide and latanoprost on the 24-hour variation in intraocular pressure (IOP) in primary open-angle glaucoma (POAG) patients first treated with timolol and latanoprost. METHODS We studied 30 eyes from 30 POAG patients previously treated with latanoprost monotherapy. After a washout of four weeks in both eyes, all patients were treate...

OBJECTIVE To compare the ocular hypotensive effect of the commercially available preparations of bimatoprost or travoprost added to latanoprost in monkey eyes with laser-induced unilateral glaucoma. METHODS Four monkeys with unilateral laser-induced glaucoma were used in each treatment group and received drops in the glaucomatous eye only. Intraocular pressure (IOP) was measured hourly for 6 ...

Aim—To compare the intraocular pressure (IOP) reducing eVect of latanoprost 0.005% and 0.001%. Methods—Twenty four patients with glaucoma or ocular hypertension were randomised into two groups. Twelve patients (group 1) were given latanoprost 0.005% once daily for 4 weeks and then latanoprost 0.001% once daily for the following 4 weeks. Twelve patients (group 2) were given latanoprost 0.001% on...

the aim of this study was to determine the combination effect of latanoprost and pilocarpine on theintraocular pressure and pupil size in normal rabbits. in this study, 18 rabbits were randomized to threegroups of 6 animals each. the right eyes of rabbits in group 1 were treated topically with latanoprost, ingroup 2 with pilocarpine and in group 3 with latanoprost and pilocarpine. the left eyes...

Background: This study investigated the safety (cytotoxicity in vitro) and pharmacological effects (ocular hypotensive effects and aqueous humor concentrations in normotensive monkeys in vivo) of latanoprost formulations with benzalkonium chloride (latanoprost with BAK) and without BAK (NP). Methods: A bioequivalence study of latanoprost with BAK and NP was also conducted on human healthy volun...

Background: Latanoprost, a prostaglandin F 2a analogue, is an intraocular pressure lowering drug used in the treatment of glaucoma. Increase in eyelash number, length, pigmentation, curvature is reported after using topical Latanoprost in these patients. The aim of this study was to evaluate the effect of Latanoprost ophthalmic solution on eyelash regrowth in patients with alopecia areata.Metho...

INTRODUCTION There has been increased attention on the potential impact of the preservative benzalkonium chloride (BAK) on the ocular surface. This study compared the ocular surface tolerability of once-daily bimatoprost 0.01% and latanoprost 0.005% (both preserved with 0.02% BAK), and travoprost 0.004% preserved with sofZia™. METHODS A randomized, multicenter (15 sites), investigator-masked ...

PURPOSE To determine the efficacy and safety of latanoprost treatment for 1 year in glaucoma patients, and to evaluate the effects of switching from timolol to latanoprost therapy. METHODS Latanoprost 0.005% was topically applied once daily without masking for 6 months in 223 patients with elevated intraocular pressure after previous treatment with latanoprost once daily or 0.5% timolol twice...

BACKGROUND Benzalkonium chloride (BAK) is a common preservative in topical ocular preparations; however, prolonged use may lead to deleterious effects on the ocular surface, affecting quality of life and reducing adherence to treatment and overall outcomes. This study compared the intraocular pressure (IOP)-lowering efficacy and safety of a novel once-daily, BAK-free, fixed-dose combination of ...

AIM To compare the intraocular pressure (IOP) reducing effect of latanoprost 0.005% and 0.001%. METHODS Twenty four patients with glaucoma or ocular hypertension were randomised into two groups. Twelve patients (group 1) were given latanoprost 0.005% once daily for 4 weeks and then latanoprost 0.001% once daily for the following 4 weeks. Twelve patients (group 2) were given latanoprost 0.001%...